APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 1 - 2 μg/mL |
| 2.5 μg/mL |
| Assay dependent |
| Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
Rat Liver Tissue Lysate(GTX27943) , Human Liver Tissue Slide
PROPERTIES
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
erbB-2 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human erbB-2.The immunogen is located within the last 50 amino acids of erbB-2.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
erb-b2 receptor tyrosine kinase 2 , CD340 , HER-2 , HER-2/neu , HER2 , MLN 19 , NEU , NGL , TKR1
Cellular Localization
Nucleus
Background
The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.
Database
Research Area
DATA IMAGES
|
GTX85113 IHC-P Image
IHC-P analysis of human liver tissue using GTX85113 Her2 / ErbB2 antibody.
Working concentration : 20 μg/ml
|
|
|
GTX85113 IHC-P Image
IHC-P analysis of human liver tissue using GTX85113 Her2 / ErbB2 antibody.
Working concentration : 2.5 μg/ml
|
|
|
GTX85113 WB Image
WB analysis of rat liver tissue lysate using GTX85113 Her2 / ErbB2 antibody.
Working concentration : (A) 1 and (B) 2 μg/ml
|
REFERENCE
There are currently no references for Her2 / ErbB2 antibody (GTX85113). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Her2 / ErbB2 antibody (GTX85113). Be the first to share your experience with this product.
